Literature DB >> 33664866

MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein.

Byoung Kwon Park1, Jinsoo Kim2, Sangkyu Park3, Dongbum Kim1, Minyoung Kim2, Kyeongbin Baek2, Joon-Yong Bae4, Man-Seong Park4, Won-Keun Kim1,2, Younghee Lee3, Hyung-Joo Kwon1,2.   

Abstract

Background: The molecular interactions between viral proteins form the basis of virus production and can be used to develop strategies against virus infection. The interactions of the envelope proteins and the viral RNA-binding n class="Gene">nucleocapsid (N) protein are essential for the assembly of coronaviruses including the Middle East respiratory syndrome coronavirus (MERS-CoV).
Methods: Using co-immunoprecipitation, immunostaining, and proteomics analysis, we identified a protein interacting with the spike (S) protein in the cells infected with MERS-CoV or SARS-CoV-2. To confirm the interaction, synthetic peptides corresponding to the C-terminal domain of the S protein (Spike CD) were produced and their effect on the interaction was investigated in vitro. In vivo effect of the Spike CD peptides after cell penetration was further investigated using viral plaque formation assay. Phylogeographic analyses were conducted to deduce homology of Spike CDs and N proteins.
Results: We identified a direct interaction between the S protein and the N protein of MERS-CoV that takes place during virus assembly in infected cells. Spike CD peptides of MERS-CoV inhibited the interaction between the S and N proteins in vitro. Furthermore, cell penetration by the synthetic Spike CD peptides inhibited viral plaque formation in MERS-CoV-infected cells. Phylogeographic analyses of Spike CDs and N proteins showed high homology among betacoronavirus lineage C strains. To determine if Spike CD peptides can inhibit the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we used the same strategy and found that the SARS-CoV-2 Spike CD peptide inhibited virus replication in SARS-CoV-2-infected cells. Conclusions: We suggest that the interaction between the S protein and the N protein can be targeted to design new therapeutics against emerging coronaviruses, including SARS-CoV-2. © The author(s).

Entities:  

Keywords:  MERS-CoV; SARS-CoV-2; nucleocapsid protein; spike protein; targeting

Year:  2021        PMID: 33664866      PMCID: PMC7914343          DOI: 10.7150/thno.55647

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


  60 in total

1.  Large-scale screening for novel low-affinity extracellular protein interactions.

Authors:  K Mark Bushell; Christian Söllner; Benjamin Schuster-Boeckler; Alex Bateman; Gavin J Wright
Journal:  Genome Res       Date:  2008-02-22       Impact factor: 9.043

2.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.

Authors:  Xian-Chun Tang; Sudhakar S Agnihothram; Yongjun Jiao; Jeremy Stanhope; Rachel L Graham; Eric C Peterson; Yuval Avnir; Aimee St Clair Tallarico; Jared Sheehan; Quan Zhu; Ralph S Baric; Wayne A Marasco
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

3.  Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly.

Authors:  F Fischer; C F Stegen; P S Masters; W A Samsonoff
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.

Authors:  Shutoku Matsuyama; Naganori Nao; Kazuya Shirato; Miyuki Kawase; Shinji Saito; Ikuyo Takayama; Noriyo Nagata; Tsuyoshi Sekizuka; Hiroshi Katoh; Fumihiro Kato; Masafumi Sakata; Maino Tahara; Satoshi Kutsuna; Norio Ohmagari; Makoto Kuroda; Tadaki Suzuki; Tsutomu Kageyama; Makoto Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-12       Impact factor: 11.205

5.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

6.  Molecular interactions in the assembly of coronaviruses.

Authors:  Cornelis A M de Haan; Peter J M Rottier
Journal:  Adv Virus Res       Date:  2005       Impact factor: 9.937

7.  High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2.

Authors:  Luca Zinzula; Jerome Basquin; Stefan Bohn; Florian Beck; Sven Klumpe; Günter Pfeifer; István Nagy; Andreas Bracher; F Ulrich Hartl; Wolfgang Baumeister
Journal:  Biochem Biophys Res Commun       Date:  2020-10-03       Impact factor: 3.575

8.  Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.

Authors:  Anamika Basu; Anasua Sarkar; Ujjwal Maulik
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

9.  A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines.

Authors:  Lanying Du; Zhihua Kou; Cuiqing Ma; Xinrong Tao; Lili Wang; Guangyu Zhao; Yaoqing Chen; Fei Yu; Chien-Te K Tseng; Yusen Zhou; Shibo Jiang
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

10.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor.

Authors:  Lu Lu; Qi Liu; Yun Zhu; Kwok-Hung Chan; Lili Qin; Yuan Li; Qian Wang; Jasper Fuk-Woo Chan; Lanying Du; Fei Yu; Cuiqing Ma; Sheng Ye; Kwok-Yung Yuen; Rongguang Zhang; Shibo Jiang
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

View more
  11 in total

1.  COVID-19 therapies: do we see substantial progress?

Authors:  Lucyna Matusewicz; Marlena Golec; Aleksander Czogalla; Kazimierz Kuliczkowski; Adam Konka; Joanna Zembala-John; Aleksander F Sikorski
Journal:  Cell Mol Biol Lett       Date:  2022-05-31       Impact factor: 8.702

2.  Structure-guided affinity maturation of a novel human antibody targeting the SARS-CoV-2 nucleocapsid protein.

Authors:  Zhihong Wang; Naijing Hu; Yangyihua Zhou; Ning Shi; Beifen Shen; Longlong Luo; Jiannan Feng
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

3.  Apoptosis Enhances the Replication of Human Coronavirus OC43.

Authors:  Sony Maharjan; Mijeong Kang; Jinsoo Kim; Dongbum Kim; Sangkyu Park; Minyoung Kim; Kyeongbin Baek; Younghee Lee; Hyung-Joo Kwon
Journal:  Viruses       Date:  2021-11-01       Impact factor: 5.048

Review 4.  Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.

Authors:  Lijun Chen; Jingjing Qu; Farhin Shaheed Kalyani; Qi Zhang; Lingzhi Fan; Yangxin Fang; Yifei Li; Charlie Xiang
Journal:  Cell Mol Life Sci       Date:  2022-02-20       Impact factor: 9.207

5.  Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study.

Authors:  Christoph Wertenauer; Geovana Brenner Michael; Alexander Dressel; Caroline Pfeifer; Ulrike Hauser; Eberhard Wieland; Christian Mayer; Caren Mutschmann; Martin Roskos; Hans-Jörg Wertenauer; Angela P Moissl; Stefan Lorkowski; Winfried März
Journal:  Front Med (Lausanne)       Date:  2022-03-21

6.  Targeting the Interaction Between Spike Protein and Nucleocapsid Protein for Suppression and Detection of Human Coronavirus OC43.

Authors:  Jinsoo Kim; Minyoung Kim; Dongbum Kim; Sangkyu Park; Mijeong Kang; Kyeongbin Baek; Jun-Kyu Choi; Sony Maharjan; Madhav Akauliya; Younghee Lee; Hyung-Joo Kwon
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 8.786

7.  Differential effect of SARS-CoV-2 infection on stress granule formation in Vero and Calu-3 cells.

Authors:  Dongbum Kim; Sony Maharjan; Mijeong Kang; Jinsoo Kim; Sangkyu Park; Minyoung Kim; Kyeongbin Baek; Suyeon Kim; Jun Gyo Suh; Younghee Lee; Hyung-Joo Kwon
Journal:  Front Microbiol       Date:  2022-08-23       Impact factor: 6.064

8.  Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein.

Authors:  Jinsoo Kim; Seok Young Hwang; Dongbum Kim; Minyoung Kim; Kyeongbin Baek; Mijeong Kang; Seungchan An; Junpyo Gong; Sangkyu Park; Mahmoud Kandeel; Younghee Lee; Minsoo Noh; Hyung-Joo Kwon
Journal:  Biomol Ther (Seoul)       Date:  2022-05-13       Impact factor: 4.231

9.  Production of SARS-CoV-2 N Protein-Specific Monoclonal Antibody and Its Application in an ELISA-Based Detection System and Targeting the Interaction Between the Spike C-Terminal Domain and N Protein.

Authors:  Dongbum Kim; Jinsoo Kim; Sangkyu Park; Minyoung Kim; Kyeongbin Baek; Mijeong Kang; Jun-Kyu Choi; Sony Maharjan; Madhav Akauliya; Younghee Lee; Hyung-Joo Kwon
Journal:  Front Microbiol       Date:  2021-12-07       Impact factor: 5.640

Review 10.  Conserved Targets to Prevent Emerging Coronaviruses.

Authors:  Fernanda Gonzalez Lomeli; Nicole Elmaraghy; Anthony Castro; Claudia V Osuna Guerrero; Laura L Newcomb
Journal:  Viruses       Date:  2022-03-09       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.